Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis
Last updated Sep 8, 2026
Health Check
Last analyzed Sep 7, 2026
- Financial Health 85
- Profitability 60
- Business Quality 65
- Balance Sheet 65
- Cash Flow 60
Why this rating?
Health 67/100 — Good Quality
Entry timing is weak right now. Quality may be fine; the setup is not.
Company overview
Regeneron Pharmaceuticals, Inc. (REGN) is a Biotechnology company in the Healthcare sector. Compound Radar rates Regeneron Pharmaceuticals, Inc. 67/100 (Good Quality) due to solid business quality, strong revenue growth, and manageable leverage.
Investment profile
- Quality Moderate
- Growth Strong
- Balance Sheet Adequate
- Valuation Attractive
Financial highlights
Valuation
- P/E 20.06
- Forward P/E 13.37
- PEG 1.17
- EV/Revenue 4.98
Profitability
- Revenue Growth 16.7%
- Gross Margin 44.5%
- Operating Margin 33.1%
- Net Margin 27.9%
- ROE 14.0%
Financial strength
- Cash $7.99B
- Debt $2.71B
- Net Cash $5.29B
- Free Cash Flow $3.77B
- Current Ratio 3.34
Similar companies
Peers in Biotechnology, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Aurinia Pharmaceuticals Inc. Biotechnology AUPH$16.07 83 Health 83 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Incyte Corporation Biotechnology INCY$124.40 82 Health 82 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Catalyst Pharmaceuticals Inc Biotechnology CPRX$31.49 81 Health 81 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Alnylam Pharmaceuticals, Inc. Biotechnology ALNY$260.10 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Halozyme Therapeutics, Inc. Biotechnology HALO$108.31 77 Health 77 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Vertex Pharmaceuticals Incorporated Biotechnology VRTX$528.90 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Harmony Biosciences Holdings, Inc. Biotechnology HRMY$42.07 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- ACADIA Pharmaceuticals Inc. Biotechnology ACAD$27.58 75 Health 75 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Regeneron Pharmaceuticals, Inc. (REGN).